Member Info for Soupdragon78

Here you go FX, this is where they will have the poster.

https://twitter.com/ianjarroldaluk/status/1566686425734696961?s=21&t=_ctg5eY7BF3cdqVLjQ5kIQ

True, although it is just a huge hall with loads of other posters up, they then just wait to see who wanders past and shows interest.

Agree on the need for a large independent investor FX.

The ERS is more of a congress for those working in the speciality areas of research, attended by doctors and medical professionals, not really for investors. Likely why NFX are being represented by Simon Cruwys and Bob Humphries rather than anyone from the company in person.

Its more about getting the papers published and peer reviewed.

Tomorrow morning 8.30 to 9.30 their time.

To be fair the last twits post from them about NFX was talking about yoga sessions, nearly as good as when they posted about a plotline of someone having a cough on an episode of neighbours.

Nice to see people posting pictures of their thematic poster sessions from the ERS Congress. All looking proud and excited to be there.
Can’t wait for NFX and their PR consultants to be doing the same…. :-\

Yay! Welcome back foremagnus! Good to see Mulder has finally remembered your log in details!

Lots of talk online about the start of the ERS congress, loads of people talking about what they are looking forward to.
Good job we’ve got a top PR company promoting NfX, I’m sure lots of people will be aware of them.

Filter, the same resolution was in previous years. Probably gives them flexibility with placings.

It was resolution 13 last year, and 12 the year before.

Because IFC would have to actually do something.

Hopefully these links work, I’m doing this on my phone and the ERS online programme site has changed and not so easy to use.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.ers/abstract_2022/94093.html.pdf

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.ers/abstract_2022/94096.html.pdf

I’m also not sure anyone from the company is attending the ERS in person.
DG is the Exec Director so doesn’t really fall under his remit.

Seems to have been some pi averaging down enabling CPI to sell.

It’s a shame the company PR consultants aren’t promoting the ERS poster session on LinkedIn etc, it’s as if they don’t want to tell the industry what the company is doing.
Online you see loads of prominent companies and Doctors talking about how excited they are to be going to the congress, yet nothing from the NFX accounts saying a single thing. :-(

Jiving, its from Allenby who got the timescales from NFX management.

It’s more about getting an outlicensing deal than waiting for them getting a product to market anyway.

“In the ‘traditional’ biotech model, drug development is a 10-year minimum process. With abbreviated timelines, a repurposed new physical form could be on the market as early as 2029 in US and Europe and 2030 in Japan following a bridging study, with patent expiry in 2038 (not including potentially available patent term extensions). We consider that the route of development and the fact that underlying drug is already known means that there is a higher likelihood of approval than via the standard drug development model, balancing the fact that NXP002 is a preclinical programme, but with the existing body of tranilast safety and PK data that NFX can leverage”

Anyway, should be NXP004 news in the near term.

Jiving, those were the companies timelines, the 2029 date is when they start the registration after the trials.
The trials have to be done and don’t get done quicker regardless of whether Kissei have 40 years of data.

Oh and by the way, at the £7.80 valuation, this means that Simon Yaxleys 10m shares in Oxilio are worth £78m quid.

Interesting to now see Oxilio’s confirmation statement following their latest allotment of shares.

Now, their website says they raised 750k cash, but the companies house statement shows they only raised 270k.
(They issued 34,491 shares at £7.80 each)

Hmmm…